Oncology · Colorectal Cancer
The identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 6/17/2026, 6:33:23 AM
Assessment confidence: 63% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 15 ranked evidence items (7 high-relevance).
Oncology integrating tailored surveillance strategies based on age and treatment history for colorectal cancer survivors. The strongest clinical anchor is Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Ca (ClinicalTrials.gov), sub-indication match (colorectal cancer); entity match (pfizer). In colorectal cancer, 5 regulatory and 1 competitive items passed relevance filtering for Pfizer.
The most relevant competitive pressure comes from Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma (Humanexa Signals) — entity match (oncology). Understanding risk factors for second primary cancers can inform surveillance strategies and treatment protocols, impacting patient management in oncology.
Regulatory risk is concentrated around Oncology (Cancer)/Hematologic Malignancies Approval Notifications (FDA). Entity match (oncology); Regulatory pathway relevance (approval). As new surveillance guidelines emerge, companies may need to adapt their clinical trial designs and product labeling to comply with updated standards, affecting approval timelines.
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (approval)
FDA document
View sourceFDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View sourceSunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceJanus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceStudy of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Ca
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Entity match (pfizer)
FDA document
View sourceThe Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Entity match (oncology)
FDA document
View sourceA Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Sig
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View sourceGene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma
Humanexa Signalsmedium relevance
Entity match (oncology)
Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC
Humanexa Signalslow relevance
Entity match (oncology)
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (colorectal cancer)
FDA document
View sourceAn orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (colorectal cancer)
FDA document
View sourceLidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (colorectal cancer)
FDA document
View sourceDiscovery of a novel and potent KRAS(G12V)-targeting peptide with antiproliferative activity against colorectal cancer cells.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (colorectal cancer)
FDA document
View sourceGut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.
PubMedhigh relevance
Sub-indication match (colorectal cancer); Entity match (colorectal cancer)
FDA document
View sourceNeoadjuvant immunochemotherapy and postoperative acute hypoxemic respiratory failure in thoracic surgery: a multicentre cohort study.
PubMedmedium relevance
Sponsor/company relevance (Pfizer); Patient population match (adjuvant)
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe identification of risk factors for second primary cancers in colorectal cancer survivors is critical for developing targeted surveillance strategies. This can significantly influence treatment protocols and patient management within oncology portfolios.
Tailored surveillance strategies may lead to increased demand for specific oncology therapies, potentially impacting market share and revenue for companies involved in colorectal cancer treatment.
As new surveillance guidelines emerge, companies may need to adapt their clinical trial designs and product labeling to comply with updated standards, affecting approval timelines.
Monitor developments in surveillance guidelines and potential new therapies targeting second primary cancers in CRC survivors.
Track for follow-up milestones; no immediate action required.